The pathogenesis of psoriasis and palmoplantar pustulosis induced by Tumor Necrosis Factor inhibitors (TNFi) is largely unknown. Only one study, in 9 inflammatory bowel disease patients, investigated the relation with infliximab drug levels in the development of psoriasis or palmoplantar pustulosis and demonstrated no relation with of trough concentrations in these events (1). However, psoriasis and palmoplantar pustulosis were not studied separately. Objectives: To study the differences in drug levels and antidrug antibodies (ADA) of TNFi in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients who developed de novo psoriasis, palmoplantar pustulosis and those who did not develop skin adverse events. Methods: In this retrospective study data was collected from the observational cohorts of Reade of consecutive RA and AS patients in whom TNFi was started. At every visit, serum samples were collected. We quantified the samples before/on time of event of the patients who developed psoriasis or palmoplantar pustulosis, for the patients with no skin adverse events (control group) at 24 or 28 weeks. Drug levels and ADA were measured with an Enzyme-linked immunosorbent assay and antibody binding test respectively. Results: A total of 830 TNFi naive patients with RA and AS were included, of whom 21 developed psoriasis (n=11) or palmoplantar pustulosis (n=10). These patients were only observed in the adalimumab and etanercept cohorts. Sixteen patients with an event and 585 patients in the control group had serum samples available to quantify drug levels and ADA. No statistical significant differences were found in drug levels of adalimumab and etanercept for both RA and AS patients (table 1) . Moreover, no statistical significant differences were observed in the detection of ADA between the three groups. However, no ADA were detected in patients who developed psoriasis or palmoplantar pustulosis compared to the overall 13.9% of the RA patients and 25.5% in AS patients.
. Differences in drug levels and detection of anti-drug antibodies between palmoplantar pustulosis, psoriasis and control group Druglevels Drug levels Anti-drug adalimumab etanercept antibodies (μg/ml; median (IQR) (μg/ml); median (IQR) adalimumab, no. (%) RA Palmoplantar pustulosis n=3 7,6 (0,01-12,0) n=1 4,4 n=3 0 (0) Psoriasis n=3 8,5 (6,5-10,0) n=2 2,3 (1,5-3,1) n=2 0 (0) Control group n=153 7,4 (4,0-10,0) n=89 2.7 (1.9-3.9) n=151 21 (13,9) p-value 0,992 0,380 0,674 AS Palmoplantar pustulosis n=3 9,0 (6,5-10,0) n=1 1,7 n=3 0 (0) Psoriasis n=1 10, 0 n=2 1,3 (0,8-1,7) n=1 0 (0) Control group n=46 8,5 (3,7-11,3) n=99 2.6 (1. Background: Despite many efforts, to date there has been no focused attempt to derive a robust estimate of the prevalence of rheumatic diseases (RDs) to quantify how this is influenced by other factors than them examined in every local study, however, the problems magnitude is rising and due the demographic transition and the increase in the life expectancy Objectives: To determine, through a systematic review and meta-analysis, the prevalence of RDs in the adult general population and explore its heterogeneity Methods: MEDLINE, EMBASE, BIREME, LILLACS and Web of Science were searched using a search strategy combining key words and related databasespecific subject terms to identify relevant cross-sectional based on COPCORD methodology studies. Also was developed a manual search. Included articles were assessed for risk of bias and quality based on the STROBE statement. Prevalence figures for RDs were analyzed according to female percentage of sampled individuals, mean age and sample size. A mixed effect model was used to obtain the combined prevalence and a meta-regression to estimate the effects of other variables Results: 44 out from 127 papers were included in English, Spanish or Portuguese. Estimates for any RDs prevalence ranged from 7.2% to 62.3% (26.9%; 95% CI 18.3%>25.6%). For rheumatoid arthritis (RA), the prevalence varied between 0.2% and 6.2% (1.04%; 95% CI 0.4%>1.6%); fibromyalgia (FM) had a mean prevalence of 2.1% (95% CI 1.0%>3.2%) and osteoarthritis: 13.5% (95% CI: 10.6%>16.4%). SLE (systematic lupus erythematosus) was the less frequent condition with average prevalence of 0.14% (95% CI: 0.005%>0.28%). The random-effects pooled prevalence for any RDs was 25% (95% CI: 18.0%, 31.1%). Prevalence was higher in studies with bigger sample size (random effect coefficient: 0.0014, p=002). There was evidence of relevant heterogeneity in the analysis (p<0,001) and for RDs, RA and FM the sample size was positively associated to the perceived heterogeneity. No effects were found for SLE Conclusions: It was found significant variation among the prevalence across this
